<DOC>
	<DOCNO>NCT02634307</DOCNO>
	<brief_summary>This study evaluate long-term safety tolerability ALKS 8700 treatment Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_summary>
	<brief_title>A Study ALKS 8700 Adults With Relapsing Remitting Multiple Sclerosis ( MS ) ( EVOLVE-MS Study )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Has confirm diagnosis RRMS Neurologically stable evidence relapse within 30 day prior Visit 2 Additional criterion may apply Subject pregnant breastfeeding plan become pregnant begin breastfeed point study 30 day study drug administration Diagnosis primary progressive secondary progressive , progressive relapse MS History clinically significant cardiovascular , pulmonary , gastrointestinal ( inflammatory bowel disease [ IBD ] ; Crohn 's disease , ulcerative colitis ) , dermatologic , psychiatric , neurologic ( MS ) , and/or major disease would preclude participation clinical trial History myocardial infarction , include silent myocardial infarction identify ECG , unstable angina Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>dimethyl fumarate</keyword>
	<keyword>DMF</keyword>
</DOC>